Last reviewed · How we verify

Liposome bupivacaine

Catherine Vandepitte, M.D. · FDA-approved active Small molecule

Liposome bupivacaine is a long-acting local anesthetic that uses liposomal encapsulation to extend the duration of bupivacaine's nerve-blocking effects.

Liposome bupivacaine is a long-acting local anesthetic that uses liposomal encapsulation to extend the duration of bupivacaine's nerve-blocking effects. Used for Infiltration anesthesia and nerve block in surgical procedures, Postoperative analgesia.

At a glance

Generic nameLiposome bupivacaine
Also known asExparel, Bupivacaine Liposome, Injectable Suspension, bupivacaine
SponsorCatherine Vandepitte, M.D.
Drug classLocal anesthetic (liposomal formulation)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is an amide local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. By encapsulating bupivacaine in liposomes, the formulation provides sustained release of the active drug, extending anesthesia duration from hours to up to 72 hours, reducing the need for repeated dosing or opioid supplementation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: